ClinicalTrials.gg
CompletedNCT02125604TOLERATEUpdated Apr 18, 2017Results posted

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany

A Phase 4 interventional study of dimethyl fumarate in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 19 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.

Sponsored by Biogen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
214
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
8th of 22
214 · median 61
Started
2014
with 2 others
Phase 4
9 of 22
none open now
Registered
9th of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 4, and was the 9th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by participants with relapsing-remitting multiple sclerosis initiating therapy with BG00012 (dimethyl fumarate, DMF) in the clinical practice setting.

The secondary objectives of this study in this study population are as follows: to evaluate gastrointestinal-related events requiring symptomatic therapy and the role of those therapies over time; to evaluate gastrointestinal-related events that lead to a physician's decision to manage the events with BG00012 dose modification; and to evaluate gastrointestinal-related events that lead to BG00012 discontinuation after the use of symptomatic therapy.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis

Keywords

  • Gastrointestinal event
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a confirmed diagnosis of relapsing-remitting multiple sclerosis according to the current McDonald Criteria and satisfy the therapeutic indication as described in the official local registration for Tecfidera (dimethyl fumarate)
  • Naïve to dimethyl fumarate and fumaric acid esters

Key Exclusion Criteria:

  • Female subjects who are currently pregnant or breastfeeding or who are considering becoming pregnant while in the study
  • History of significant gastrointestinal disease (e.g., irritable bowel disease, peptic ulcer disease, history of major gastrointestinal surgeries), or chronic use of gastrointestinal-related symptomatic therapy as determined by the Investigator (or ≥ 7 consecutive days of gastrointestinal-related symptomatic therapy
  • Known active
  • History of anaphylaxis or severe allergic reactions or known drug
  • Current use of B vitamin supplements
  • In the opinion of the Investigator, blood test values suggestive of a low lymphocyte count or renal or hepatic impairment, as described in the product label precautions for use

NOTE: Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Dimethyl Fumarate

    Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.

    Drug: dimethyl fumarate

Interventions

  • capsules administered according to the prevailing product label

    Also known as: BG00012, Tecfidera, DMF

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal Symptom Scale (MOGISS)

    The MOGISS is a questionnaire about the severity of overall gastrointestinal-related events, including specifically symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence for 24 hours before the AM dose. Participants who rated the intensity of symptoms reported on the MOGISS and included each symptomatic therapy used in the eDiary are presented.

    Time frame: Up to Week 12

  2. Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Acute Gastrointestinal Symptom Scale (MAGISS)

    The MAGISS is a questionnaire in which participants reported overall acute gastrointestinal-related events, (especially symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) for each 10 hours after the AM and PM doses of study drug. Participants who rated the intensity of gastrointestinal-related events reported on MAGISS, included the duration of the gastrointestinal-related events and each symptomatic therapy used in the eDiary are presented.

    Time frame: Up to Week 12

  3. Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS

    The MOGISS is a questionnaire about overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. MOGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.

    Time frame: Up to Week 12

  4. Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MAGISS

    The MAGISS is a questionnaire about the overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) following drug administration (acute symptoms). MAGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.

    Time frame: Up to Week 12

  5. Duration of Gastrointestinal-Related Events in Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS

    The percentage of days with GI events as reported on MOGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with \[GI\] events / # of days tolerability scale completed). The symptomatic therapy (ST) categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.

    Time frame: Up to Week 12

  6. Duration of Gastrointestinal-Related Events in Participants Who Utilize Symptomatic Therapy During the 12-Week Treatment Period, MAGISS

    Percentage of days with GI events as reported on MAGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with \[GI\] events / # of days tolerability scale completed). The ST categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.

    Time frame: Up to Week 12

Secondary outcomes

  1. Percentage of Participants Who First Took Symptomatic Therapy for Gastrointestinal-Related Events at Weeks 4, 8, and 12

    The cumulative percentage of dimethyl fumarate-treated participants with relapsing-remitting multiple sclerosis who required symptomatic therapy up to Week 4, Week 8, and Week 12 were estimated using the Kaplan-Meier method.

    Time frame: Week 4, Week 8, Week 12

  2. Number of Participants Who Used Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category

    Symptomatic therapies were classified into 10 main categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (includes Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon \& Iberogast, Iberogast \& Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (non-steroidal anti-inflammatory drug \[NSAID\]; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). Participants may have taken \> 1 symptomatic therapy but were counted only once for the 'All therapies' summary.

    Time frame: Up to Week 12

  3. Duration of Use of Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category

    Symptomatic therapies were classified into 10 categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (eg, Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon \& Iberogast, Iberogast \& Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (NSAID; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in 'All therapies'.

    Time frame: Up to Week 12

  4. Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events

    Dose reductions are defined as participants who take any dimethyl fumarate 120 mg or 0 mg since initiation of dimethyl fumarate 240 mg.

    Time frame: Up to Week 12

  5. Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events

    Time frame: Up to Week 12

07

Results

Posted Apr 18, 2017

Participant flow

Participant flow — Overall Study
MilestoneDimethyl Fumarate
Started211
Completed180
Not completed31
Withdrew: Other4
Withdrew: Investigator decision1
Withdrew: Lost to follow-up2
Withdrew: Consent withdrawn4
Withdrew: Adverse event20

Outcome measures

PrimaryNumber of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal Symptom Scale (MOGISS)

The MOGISS is a questionnaire about the severity of overall gastrointestinal-related events, including specifically symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence for 24 hours before the AM dose. Participants who rated the intensity of symptoms reported on the MOGISS and included each symptomatic therapy used in the eDiary are presented.

Time frame:
Up to Week 12
Reported as:
Number · Participants
Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal Symptom Scale (MOGISS)
ParticipantsDimethyl Fumarate
Overall Treatment Period; n=21182
Weeks 1-4; n=21171
Weeks 5-8; n=18633
Weeks 9-12; n=17822
PrimaryNumber of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Acute Gastrointestinal Symptom Scale (MAGISS)

The MAGISS is a questionnaire in which participants reported overall acute gastrointestinal-related events, (especially symptoms of nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) for each 10 hours after the AM and PM doses of study drug. Participants who rated the intensity of gastrointestinal-related events reported on MAGISS, included the duration of the gastrointestinal-related events and each symptomatic therapy used in the eDiary are presented.

Time frame:
Up to Week 12
Reported as:
Number · Participants
Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Acute Gastrointestinal Symptom Scale (MAGISS)
ParticipantsDimethyl Fumarate
Overall Treatment Period; n=21183
Weeks 1-4; n=21172
Weeks 5-8; n=18934
Weeks 9-12; n=18026
PrimaryWorst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS

The MOGISS is a questionnaire about overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. MOGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.

Time frame:
Up to Week 12
Reported as:
Mean · units on a scale
Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS
units on a scaleDimethyl Fumarate
Overall treatment period; n=845.94 ± 2.427
Week 1-4; n=735.75 ± 2.554
Week 5-8; n=383.53 ± 2.533
Week 9-12; n=293.1 ± 2.568
PrimaryWorst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MAGISS

The MAGISS is a questionnaire about the overall events related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) following drug administration (acute symptoms). MAGISS is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. The worst overall severity score for gastrointestinal-related events was calculated for each participant for the overall treatment period of 12 weeks, and for each 4-week period therein.

Time frame:
Up to Week 12
Reported as:
Mean · units on a scale
Worst Severity Of Gastrointestinal-Related Events In Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MAGISS
units on a scaleDimethyl Fumarate
Overall treatment period; n=845.93 ± 2.516
Week 1-4; n=735.88 ± 2.614
Week 5-8; n=393.31 ± 2.307
Week 9-12; n=293.55 ± 2.772
PrimaryDuration of Gastrointestinal-Related Events in Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS

The percentage of days with GI events as reported on MOGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with \[GI\] events / # of days tolerability scale completed). The symptomatic therapy (ST) categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.

Time frame:
Up to Week 12
Reported as:
Mean · percentage of days
Duration of Gastrointestinal-Related Events in Participants Who Utilized Symptomatic Therapy During the 12-Week Treatment Period, MOGISS
percentage of daysDimethyl Fumarate
Overall treatment period; Any ST (n=84)38.13 ± 29.263
Overall treatment period; ST1 (n=50)42.08 ± 27.495
Overall treatment period; ST2 (n=26)36.98 ± 29.754
Overall treatment period; ST3 (n=20)39.61 ± 29.197
Overall treatment period; ST4 (n=16)48.15 ± 30.140
Overall treatment period; ST5 (n=10)45.94 ± 27.147
Overall treatment period; ST6 (n=8)44.33 ± 29.095
Overall treatment period; ST7 (n=6)57.52 ± 21.998
Overall treatment period; ST8 (n=5)52.71 ± 31.829
Overall treatment period; ST9 (n=3)32.78 ± 26.995
Overall treatment period; ST10 (n=2)9.20 ± 2.137
Week 1-4; Any ST (n=73)49.58 ± 29.547
Week 1-4; ST1 (n=44)53.92 ± 27.197
Week 1-4; ST2 (n=23)49.53 ± 32.012
Week 1-4; ST3 (n=18)55.31 ± 29.869
Week 1-4; ST4 (n=13)56.63 ± 25.764
Week 1-4; ST5 (n=9)44.42 ± 32.470
Week 1-4; ST6 (n=6)48.48 ± 35.539
Week 1-4; ST7 (n=6)69.78 ± 24.808
Week 1-4; ST8 (n=5)66.43 ± 31.400
Week 1-4; ST9 (n=3)41.41 ± 34.085
Week 1-4; ST10 (n=0)NA ± NA
Week 5-8; Any ST (n=38)41.55 ± 38.612
Week 5-8; ST1 (n=23)44.04 ± 41.414
Week 5-8; ST2 (n=3)41.67 ± 52.042
Week 5-8; ST3 (n=8)37.45 ± 37.388
Week 5-8; ST4 (n=3)69.14 ± 44.186
Week 5-8; ST5 (n=3)63.75 ± 31.332
Week 5-8; ST6 (n=3)70.42 ± 25.699
Week 5-8; ST7 (n=1)35.71 ± NA
Week 5-8; ST8 (n=2)56.88 ± 40.032
Week 5-8; ST9 (n=0)NA ± NA
Week 5-8; ST10 (n=2)1.79 ± 2.525
Week 9-12; Any ST (n=29)43.27 ± 42.322
Week 9-12; ST1 (n=15)47.66 ± 43.191
Week 9-12; ST2 (n=3)82.72 ± 29.937
Week 9-12; ST3 (n=6)48.85 ± 50.931
Week 9-12; ST4 (n=4)22.12 ± 20.834
Week 9-12; ST5 (n=2)62.50 ± 53.033
Week 9-12; ST6 (n=0)NA ± NA
Week 9-12; ST7 (n=0)NA ± NA
Week 9-12; ST8 (n=2)9.26 ± 13.095
Week 9-12; ST9 (n=0)NA ± NA
Week 9-12; ST10 (n=0)NA ± NA
SecondaryPercentage of Participants Who First Took Symptomatic Therapy for Gastrointestinal-Related Events at Weeks 4, 8, and 12

The cumulative percentage of dimethyl fumarate-treated participants with relapsing-remitting multiple sclerosis who required symptomatic therapy up to Week 4, Week 8, and Week 12 were estimated using the Kaplan-Meier method.

Time frame:
Week 4, Week 8, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who First Took Symptomatic Therapy for Gastrointestinal-Related Events at Weeks 4, 8, and 12
percentage of participantsDimethyl Fumarate
Week 435.3
Week 838.4
Week 1241.1
SecondaryNumber of Participants Who Used Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category

Symptomatic therapies were classified into 10 main categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (includes Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon \& Iberogast, Iberogast \& Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (non-steroidal anti-inflammatory drug \[NSAID\]; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). Participants may have taken \> 1 symptomatic therapy but were counted only once for the 'All therapies' summary.

Time frame:
Up to Week 12
Reported as:
Number · participants
Number of Participants Who Used Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category
participantsDimethyl Fumarate
Overall treatment period (OTP): All therapies84
OTP: Anti-acid production50
OTP: Anti-bloating/anti-constipation agent26
OTP: Multi-target/herbal agents20
OTP: Anti-diarrheal (anti-peristaltic)16
OTP: Analgesic (NSAID)10
OTP: Anti-emetic (central)8
OTP: Anti-emetic (pro-kinetic)6
OTP: Antacid5
OTP: Other3
OTP: Laxative (pro-kinetic)2
Week 1-4: All therapies73
Week 1-4: Anti-acid production44
Week 1-4: Anti-bloating/anti-constipation agent23
Week 1-4: Multi-target/herbal agents18
Week 1-4: Anti-diarrheal (anti-peristaltic)13
Week 1-4: Analgesic (NSAID)9
Week 1-4: Anti-emetic (central)6
Week 1-4: Anti-emetic (pro-kinetic)6
Week 1-4: Antacid5
Week 1-4: Other3
Week 5-8: All therapies38
Week 5-8: Anti-acid production23
Week 5-8: Multi-target/herbal agents8
Week 5-8: Analgesic (NSAID)3
Week 5-8: Anti-bloating/anti-constipation agent3
Week 5-8: Anti-diarrheal (anti-peristaltic)3
Week 5-8: Anti-emetic (central)3
Week 5-8: Antacid2
Week 5-8: Laxative (pro-kinetic)2
Week 5-8: Anti-emetic (pro-kinetic)1
Week 9-12: All therapies29
Week 9-12: Anti-acid production15
Week 9-12: Multi-target/herbal agents6
Week 9-12: Anti-diarrheal (anti-peristaltic)4
Week 9-12: Anti-bloating.anti-constipation agent3
Week 9-12: Analgesic (NSAID)2
Week 9-12: Antacid2
SecondaryDuration of Use of Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category

Symptomatic therapies were classified into 10 categories: anti-acid production (eg, pantoprazole, omeprazole, esomeprazole, ranitidine); anti-bloating/anti-constipation agents (eg, hyoscine butylbromide, sodium picosulfate, Agiolax, dimeticone, lactulose, Movicol, simethicone); multitarget/herbal agents (eg, Iberogast, Gaviscon, amaratropfen, Wikalin, Gaviscon \& Iberogast, Iberogast \& Wikalin); anti-diarrheal (anti-peristaltic; loperamide, racecadotril); analgesic (NSAID; ibuprofen, paracetamol, metamizole); anti-emetic (central; dimenhydrinate, domperidone); anti-emetic (pro-kinetic; metoclopramide); anti-acid (calcium carbonate, magaldrate, sodium hydrogen carbonate, sodium hydroxide/aluminium oxide, Talcid); other (Saccharomyces boulardii, carbon tablet, Lactobacillus acidophilus); laxative (pro-kinetic; bisacodyl). If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in 'All therapies'.

Time frame:
Up to Week 12
Reported as:
Mean · days
Duration of Use of Symptomatic Therapies for Gastrointestinal-Related Events During the 12-Week Treatment Period, by Category
daysDimethyl Fumarate
OTP: All therapies; n=8413.15 ± 19.21
OTP: Anti-acid production; n=5016.62 ± 22.21
OTP: Anti-bloating/anti-constipation agent; n=262.42 ± 1.81
OTP: Multi-target/herbal agents; n=209.40 ± 13.95
OTP: Anti-diarrheal (anti-peristaltic); n=163.13 ± 2.53
OTP: Analgesic (NSAID); n=103.10 ± 1.73
OTP: Anti-emetic (central); n=83.25 ± 4.43
OTP: Anti-emetic (pro-kinetic); n=61.83 ± 0.98
OTP: Antacid; n=53.60 ± 4.22
OTP: Other; n=31.67 ± 0.58
OTP: Laxative (pro-kinetic); n=21.00 ± 0.00
Week 1-4: All therapies; n=736.03 ± 6.12
Week 1-4: Anti-acid production; n=447.07 ± 6.73
Week 1-4: Anti-bloating/anti-constipation; n=232.30 ± 1.89
Week 1-4: Multi-target/herbal agents; n=183.78 ± 3.06
Week 1-4: Anti-diarrheal (anti-peristaltic); n=132.62 ± 1.45
Week 1-4: Analgesic (NSAID); n=92.11 ± 0.93
Week 1-4: Anti-emetic (central); n=63.17 ± 3.92
Week 1-4: Anti-emetic (pro-kinetic); n=61.67 ± 0.82
Week 1-4: Antacid; n=51.80 ± 1.30
Week 1-4: Other; n=31.67 ± 0.58
Week 5-8: All therapies; n=3810.08 ± 10.56
Week 5-8: Anti-acid production; n=2313.00 ± 11.14
Week 5-8: Multi-target/herbal agents; n=88.50 ± 10.45
Week 5-8: Analgesic (NSAID); n=32.00 ± 1.00
Week 5-8: Anti-bloating/anti-constipation; n=31.33 ± 0.58
Week 5-8: Anti-diarrheal (anti-peristaltic); n=34.00 ± 3.61
Week 5-8: Anti-emetic (central); n=32.33 ± 1.15
Week 5-8: Antacid; n=22.50 ± 2.12
Week 5-8: Laxative (pro-kinetic); n=21.00 ± 0.00
Week 5-8: Anti-emetic (prokinetic); n=11.00 ± NA
Week 9-12: All therapies; n=299.72 ± 10.31
Week 9-12: Anti-acid production; n=1514.73 ± 10.91
Week 9-12: Multi-target/herbal agents; n=68.67 ± 8.57
Week 9-12: Anti-diarrheal (anti-peristaltic); n=41.00 ± 0.00
Week 9-12: Anti-bloating/anti-constipation; n=32.00 ± 1.00
Week 9-12: Analgesic (NSAID); n=23.00 ± 0.00
Week 9-12: Antacid; n=22.00 ± 1.41
SecondaryPercentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events

Dose reductions are defined as participants who take any dimethyl fumarate 120 mg or 0 mg since initiation of dimethyl fumarate 240 mg.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events
percentage of participantsDimethyl Fumarate
Percentage of Participants Who Required Dimethyl Fumarate Dose Reduction In Response To Gastrointestinal-Related Events34.6
SecondaryPercentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events
Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events
percentage of participantsDimethyl Fumarate
Percentage of Participants Who Discontinued Dimethyl Fumarate Due To Gastrointestinal-Related Treatment-Emergent Adverse Events6.6
PrimaryDuration of Gastrointestinal-Related Events in Participants Who Utilize Symptomatic Therapy During the 12-Week Treatment Period, MAGISS

Percentage of days with GI events as reported on MAGISS was calculated for each participant and each analysis period using the following formula: 100 x (# of days with \[GI\] events / # of days tolerability scale completed). The ST categories were provided by Biogen Medical team as follows: ST1=anti-acid production; ST2=anti-bloating/anti-constipation agent; ST3=multitarget/ herbal agents; ST4=anti-diarrheal (anti-peristaltic); ST5=analgesic (NSAID); ST6=anti-emetic (central); ST7=anti-emetic (pro-kinetic); ST8=antacid; ST9=other; ST10=laxative (pro-kinetic). Overall GI events were reported in the second day after the dose. Relative day for Overall GI events = assessment date-first dose date.

Time frame:
Up to Week 12
Reported as:
Mean · percentage of days
Duration of Gastrointestinal-Related Events in Participants Who Utilize Symptomatic Therapy During the 12-Week Treatment Period, MAGISS
percentage of daysDimethyl Fumarate
Overall treatment period; Any ST (n=84)38.20 ± 30.516
Overall treatment period; ST1 (n=50)41.29 ± 29.517
Overall treatment period; ST2 (n=26)33.67 ± 27.310
Overall treatment period; ST3 (n=20)39.28 ± 29.165
Overall treatment period; ST4 (n=16)49.94 ± 33.291
Overall treatment period; ST5 (n=10)45.65 ± 27.118
Overall treatment period; ST6 (n=8)44.71 ± 30.374
Overall treatment period; ST7 (n=6)55.32 ± 23.097
Overall treatment period; ST8 (n=5)53.42 ± 31.443
Overall treatment period; ST9 (n=3)36.92 ± 27.800
Overall treatment period; ST10 (n=2)10.88 ± 1.924
Week 1-4; Any ST (n=73)51.03 ± 30.360
Week 1-4; ST1 (n=44)54.41 ± 29.608
Week 1-4; ST2 (n=23)47.84 ± 30.764
Week 1-4; ST3 (n=18)56.67 ± 30.711
Week 1-4; ST4 (n=13)58.90 ± 27.111
Week 1-4; ST5 (n=9)53.74 ± 32.304
Week 1-4; ST6 (n=6)46.43 ± 33.221
Week 1-4; ST7 (n=6)67.54 ± 25.296
Week 1-4; ST8 (n=5)69.86 ± 28.919
Week 1-4; ST9 (n=3)47.61 ± 47.61
Week 1-4; ST10 (n=0)NA ± NA
Week 5-8; Any ST (n=38)40.59 ± 37.836
Week 5-8; ST1 (n=23)41.59 ± 41.442
Week 5-8; ST2 (n=3)47.14 ± 45.781
Week 5-8; ST3 (n=8)38.50 ± 35.493
Week 5-8; ST4 (n=3)62.58 ± 45.775
Week 5-8; ST5 (n=3)56.33 ± 33.011
Week 5-8; ST6 (n=3)71.61 ± 24.587
Week 5-8; ST7 (n=1)35.71 ± NA
Week 5-8; ST8 (n=2)62.24 ± 32.456
Week 5-8; ST9 (n=0)NA ± NA
Week 5-8; ST10 (n=2)10.00 ± 14.142
Week 9-12; Any ST (n=29)41.28 ± 42.466
Week 9-12; ST1 (n=15)44.24 ± 44.754
Week 9-12; ST2 (n=3)76.19 ± 41.239
Week 9-12; ST3 (n=6)51.99 ± 50.113
Week 9-12; ST4 (n=4)15.48 ± 10.178
Week 9-12; ST5 (n=2)63.16 ± 52.103
Week 9-12; ST6 (n=0)NA ± NA
Week 9-12; ST7 (n=0)NA ± NA
Week 9-12; ST8 (n=2)13.11 ± 7.655
Week 9-12; ST9 (n=0)NA ± NA
Week 9-12; ST10 (n=0)NA ± NA

Adverse events

Collected over Serious adverse events: from signing of informed consent through last dose (up to 12 weeks (±5 days) plus 2 weeks (±5 days) follow up. Adverse events: from time of first dose of dimethyl fumarate through last dose (up to 12 weeks (±5 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dimethyl Fumarate—5/211 (2.4%)129/211 (61.1%)
Most frequent serious events
Most frequent serious events
EventDimethyl Fumarate
Multiple sclerosis relapseNervous system disorders2/211
HypersensitivityImmune system disorders1/211
Alanine aminotransferase increrasedInvestigations1/211
Aspartate aminotransferaseInvestigations1/211
Gamma-glutamyltransferaseInvestigations1/211
Alcohol abusePsychiatric disorders1/211
Most frequent other events
Most frequent other events
EventDimethyl Fumarate
FlushingVascular disorders105/211
NasopharyngitisInfections and infestations31/211
HeadacheNervous system disorders14/211
FatigueGeneral disorders12/211
PruritisSkin and subcutaneous tissue disorders12/211

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dimethyl Fumarate
Mean40.09 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)Dimethyl Fumarate
Female149
Male62
08

Study locations

19 sites
  • Research Site
    Augsburg, Germany
  • Research Site
    Bamburg, Germany
  • Research Site
    Bayreuth, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Bochum, Germany
  • Research Site
    Bonn, Germany
  • Research Site
    Erbach, Germany
  • Research Site
    Erlangen, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Leipzig, Germany
  • Research Site
    Marburg, Germany
  • Research Site
    Minden, Germany
  • Research Site
    Mittweida, Germany
  • Research Site
    Munchen, Germany
  • Research Site
    Munster, Germany
  • Research Site
    Osnabruck, Germany
  • Research Site
    Potsdam, Germany
  • Research Site
    Siegen, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Feb 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2014
First posted
Apr 29, 2014
Start
Jun 2014
Primary completionActual
Feb 2016
CompletionActual
Mar 2016
Results first posted
Apr 18, 2017
Last update
Apr 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02125604
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 29, 2014
Start date
Jun 2014
Primary completion
Feb 2016
Completion
Mar 2016
Results posted
Apr 18, 2017
Last update
Apr 18, 2017

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion